gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J 5, 3057–3063. Davison, A. J. & Moss, B. (1990). New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res 18, 4285–4286. de Lima, B. D., May, J. S. & Stevenson, P. G. (2004). Murine gammaherpesvirus 68 lacking gp150 shows defective virion release but establishes normal latency in vivo. J Virol 78, 5103–5112. Dialyna, I. A., Graham, D., Rezaee, R., Blue, C. E., Stavrianeas, N. G., Neisters, H. G., Spandidos, D. A. & Blackbourn, D. J. (2004). Anti- HHV-8/KSHV antibodies in infected individuals inhibit infection in vitro. AIDS 18, 1263–1270. Gangappa, S., Kapadia, S. B., Speck, S. H. & Virgin, H. W. (2002). Antibody to a lytic cycle viral protein decreases gammaherpesvirus latency in B-cell-deficient mice. J Virol 76, 11460–11468. Gill, M. B., Gillet, L., Colaco, S., May, J. S., de Lima, B. D. & Stevenson, P. G. (2006). Murine gammaherpesvirus-68 glycoprotein H-glycoprotein L complex is a major target for neutralizing monoclonal antibodies. J Gen Virol 87, 1465–1475. Gillet, L. & Stevenson, P. G. (2007a). Evidence for a multiprotein gamma-2 herpesvirus entry complex. J Virol 81, 13082–13091. Gillet, L. & Stevenson, P. G. (2007b). Antibody evasion by the N terminus of murid herpesvirus-4 glycoprotein B. EMBO J 26, 5131– 5142. Gillet, L., Gill, M. B., Colaco, S., Smith, C. M. & Stevenson, P. G. (2006). Murine gammaherpesvirus-68 glycoprotein B presents a difficult neutralization target to monoclonal antibodies derived from infected mice. J Gen Virol 87, 3515–3527. Gillet, L., Adler, H. & Stevenson, P. G. (2007a). Glycosaminoglycan interactions in murine gammaherpesvirus-68 infection. PLoS ONE 2, e347. Gillet, L., May, J. S. & Stevenson, P. G. (2007b). Post-exposure vaccination improves gammaherpesvirus neutralization. PLoS ONE 2, e899. Gillet, L., May, J. S., Colaco, S. & Stevenson, P. G. (2007c). The murine gammaherpesvirus-68 gp150 acts as an immunogenic decoy to limit virion neutralization. PLoS ONE 2, e705. Gillet, L., Colaco, S. & Stevenson, P. G. (2008a). The murid herpesvirus-4 gH/gL binds to glycosaminoglycans. PLoS ONE 3, e1669. Gillet, L., Colaco, S. & Stevenson, P. G. (2008b). The murid herpesvirus-4 gL regulates an entry-associated conformation change in gH. PLoS ONE 3, e2811. Gillet, L., Colaco, S. & Stevenson, P. G. (2008c). Glycoprotein B switches conformation during murid herpesvirus 4 entry. J Gen Virol 89, 1352–1363. Gillet, L., Alenquer, M., Glauser, D. L., Colaco, S., May, J. S. & Stevenson, P. G. (2009a). Glycoprotein L sets the neutralization profile of murid herpesvirus-4. J Gen Virol 90, 1202–1214. Gillet, L., May, J. S. & Stevenson, P. G. (2009b). In vivo importance of heparan sulfate-binding glycoproteins for murid herpesvirus-4 infection. J Gen Virol 90, 602–613. Gorman, S., Harvey, N. L., Moro, D., Lloyd, M. L., Voigt, V., Smith, L. M., Lawson, M. A. & Shellam, G. R. (2006). Mixed infection with multiple strains of murine cytomegalovirus occurs following simultaneous or sequential infection of immunocompetent mice. J Gen Virol 87, 1123– 1132. Heldwein, E. E., Lou, H., Bender, F. C., Cohen, G. H., Eisenberg, R. J. & Harrison, S. C. (2006). Crystal structure of glycoprotein B from herpes simplex virus 1. Science 313, 217–220. http://vir.sgmjournals.org MuHV-4 neutralization Highlander, S. L., Cai, W. H., Person, S., Levine, M. & Glorioso, J. C. (1988). Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration. J Virol 62, 1881– 1888. Janz, A., Oezel, M., Kurzeder, C., Mautner, J., Pich, D., Kost, M., Hammerschmidt, W. & Delecluse, H. J. (2000). Infectious Epstein– Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J Virol 74, 10142–10152. Kim, I. J., Fla n˜o, E., Woodland, D. L. & Blackman, M. A. (2002). Antibody-mediated control of persistent gamma-herpesvirus infec- tion. J Immunol 168, 3958–3964. Li, Q., Turk, S. M. & Hutt-Fletcher, L. M. (1995). The Epstein–Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells. J Virol 69, 3987–3994. Lopes, F. B., Colaco, S., May, J. S. & Stevenson, P. G. (2004). Characterization of the murine gamma-herpesvirus 68 glycoprotein B. J Virol 78, 13370–13375. May, J. S., Coleman, H. M., Boname, J. M. & Stevenson, P. G. (2005). Murine gammaherpesvirus-68 ORF28 encodes a non-essential virion glycoprotein. J Gen Virol 86, 919–928. Milho, R., Smith, C. M., Marques, S., Alenquer, M., May, J. S., Gillet, L., Gaspar, M., Efstathiou, S., Simas, J. P. & Stevenson, P. G. (2009). In vivo imaging of murid herpesvirus-4 infection. J Gen Virol 90, 21–32. Naranatt, P. P., Akula, S. M. & Chandran, B. (2002). Characterization of c2-human herpesvirus-8 glycoproteins gH and gL. Arch Virol 147, 1349–1370. Nazerian, K., Lee, L. F., Yanagida, N. & Ogawa, R. (1992). Protection against Marek’s disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek’s disease virus. J Virol 66, 1409–1413. Ohlin, M., Sundqvist, V. A., Mach, M., Wahren, B. & Borrebaeck, C. A. (1993). Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol 67, 703–710. Okazaki, K., Fujii, S., Takada, A. & Kida, H. (2006). The amino- terminal residue of glycoprotein B is critical for neutralization of bovine herpesvirus 1. Virus Res 115, 105–111. Pass, R. F., Zhang, C., Evans, A., Simpson, T., Andrews, W., Huang, M. L., Corey, L., Hill, J., Davis, E. & other authors (2009). Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360, 1191–1199. Roche, S., Rey, F. A., Gaudin, Y. & Bressanelli, S. (2007). Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 315, 843–848. Rosa, G. T., Gillet, L., Smith, C. M., de Lima, B. D. & Stevenson, P. G. (2007). IgG Fc receptors provide an alternative infection route for murine gamma-herpesvirus-68. PLoS ONE 2, e560. Sakamoto, K., Asanuma, H., Nakamura, T., Kanno, T., Sata, T. & Katano, H. (2010). Immune response to intranasal and intraperitoneal immunization with Kaposi’s sarcoma-associated herpesvirus in mice. Vaccine 28, 3325–3332. Smith, C. M., Rosa, G. T., May, J. S., Bennett, N. J., Mount, A. M., Belz, G. T. & Stevenson, P. G. (2006). CD4+ T cells specific for a model latency-associated antigen fail to control a gammaherpesvirus in vivo. Eur J Immunol 36, 3186–3197. Sokal, E. M., Hoppenbrouwers, K., Vandermeulen, C., Moutschen, M., L e´onard, P., Moreels, A., Haumont, M., Bollen, A., Smets, F. & Denis, M. (2007). Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo- controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein–Barr virus vaccine in healthy young adults. J Infect Dis 196, 1749–1753. 2551